Ludwig-Maximilians-University Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
First Treatments at Munich Hospital Leverage MRIdian's Precision for High-Dose Delivery and Adaptive Therapy Capabilities
CLEVELAND, March 18, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Ludwig-Maximilians-University Hospital in Munich has begun patient treatments with MRIdian® Linac, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MRI-guidance.
The first patient treated at Ludwig-Maximilians-University Hospital was treated for an ultra-central lung lesion using stereotactic body radiation therapy (SBRT), which delivers high doses of radiation to targeted areas in fewer treatment sessions than conventional radiation therapy. The goal of SBRT is to irradiate the tumor, mitigate side effects and impact to healthy surrounding tissue, and provide greater convenience to patients. Because of MRIdian's continual MRI-guided adaptive capabilities and automatic beam gating, it is well-suited to deliver SBRT treatments.
In the first six weeks of MRIdian patient treatments at Ludwig-Maximilians-University Hospital, other indications treated with MRIdian included prostate, pancreas, spine and abdominal lesions. More than 70 percent of the 110 delivered fractions were delivered using MRIdian's full-online adaptive capabilities, which enable clinicians to make treatment plan modifications, both during treatment delivery and throughout the course of treatment.
"Our MRIdian treatment schedule is filling up quickly, as so many of our patient cases can benefit from the precision afforded by MRI-guided and adapted therapy," said Stefanie Corradini, M.D., radiation oncologist and Chief of Service for the MR-guided radiotherapy program at LMU Munich. "MRIdian allows us to see and address potential changes in the size, shape and location of the lesion or surrounding anatomy, and thereby deliver higher therapeutic doses when appropriate. These capabilities will significantly benefit our patients who can now receive a more precise and personalized approach to their radiation therapy."
Currently 34 MRIdian systems are installed at hospitals around the world, where they are being used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 8,000 patients have been treated with MRIdian. For a list of treatment centers, please visit: https://viewray.com/mridian-locator.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay's financial guidance for the full year 2020 and ViewRay's conference calls to discuss its fourth quarter 2019 and year to date results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, and the timing of delivery of ViewRay's products, the timing, results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its 2019 Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
SOURCE ViewRay, Inc.
Share this article